Arrowhead Pharmaceuticals, Inc. ranks seventh on a list of 11 Best Future Stocks to Buy Now. The biotech company focuses on RNA interference therapeutics with a proprietary TRiM platform for gene silencing, making it a top player in gene-targeted treatments.

In July 2025, Arrowhead received a $100 million payment from Sarepta Therapeutics in a licensing deal, potentially earning up to $10 billion in milestone and royalty payments. The collaboration validates Arrowhead’s RNAi technology and provides strong financial support.

Arrowhead Pharmaceuticals is advancing its cardiometabolic pipeline with Phase 3 studies for zodasiran and plozasiran, targeting hypercholesterolemia and hypertriglyceridemia. The company’s NDA for plozasiran has been accepted by the FDA, with a potential approval date in November 2025.

Positive Phase 3 results reinforce Arrowhead Pharmaceuticals’ progress in bringing RNAi therapies to market. Significant reductions in triglycerides and pancreatitis highlight the efficacy of the company’s treatments, positioning it for further growth and success in the biotech sector.

Read more at Yahoo Finance: Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal